Bridgebio Pharma, Inc. (BBIO)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$68.56+0.65%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Bridgebio Pharma, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	308.39M
EPS	—	-0.518
Annual ending 2026-12-31
Revenue	—	1.03B
EPS	—	-2.751
Annual ending 2027-12-31
Revenue	—	1.65B
EPS	—	-0.424

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Execute capital allocation including $500M stock buyback	A supporting condition in Bridgebio Pharma, Inc.'s published investment case. The stated target is Complete $500 million stock repurchase program in 2026-Q1.	Intact	Stock repurchase program not executed as planned in 2026-Q1	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. The company closed a $1 billion preferred equity financing in 2026-Q2 and announced a $500 million share repurchase program in 2026-Q1. These capital allocation actions support management's stated goal to fund launches and pipeline development, showing active execution on capital strategy. Delivery assessment Oct 24, 2026
Manage operating losses and improve operating income	The company is cutting losses, improving operating income from -$139.6M to -$106M.	Under Pressure	operating income worse than -$105.96 million in 2026-Q1	Operating income: $-107.079M FY2026-Q2; GAAP. Published target: Operating income better than -$105.96 million in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 10, 2026-107,079,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 70c9b9ba-742e-4dc9-9887-bf94426e039d. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Operating income remained negative at -$105.96 million in 2026-Q1 and -$107.08 million in 2026-Q2, with increased SG&A and R&D expenses supporting commercialization and pipeline. Despite revenue growth, operating losses persist, indicating limited progress on improving operating income. Delivery assessment Oct 24, 2026
Grow revenue through Attruby and new product launches	BridgeBio grows revenue fast from Attruby and new drugs.	Intact	revenue falls below $194.5 million in 2026-Q1	Product revenue: $222.44M FY2026-Q2; reported segment. Published target: >= $194.5 million revenue in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 10, 2026222,440,000 USD · source valueLast status assessment Oct 24, 2026 Measurement source Product · reported segment FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_segment_revenue. Reference: 2026-Q2. Source status: vendor observation. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Total revenues, net increased from $194.5 million in 2026-Q1 to $243.7 million in 2026-Q2, driven primarily by U.S. Attruby net product revenue growth from $180.6 million to $222.4 million. Management has emphasized preparing for three upcoming product launches alongside Attruby's growth, and the revenue trajectory is delivering consistent growth. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.42

$0.59 → $-0.42 · observed estimates

FY2027 revenue$1.65B

$1.61B → $1.65B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.59	$1,611,333,920	7 / 18
2026-07-25	$0.57	$1,609,293,420	7 / 18
2026-07-26	$0.57	$1,609,293,420	7 / 18
2026-07-27	$0.57	$1,609,293,420	7 / 18
2026-07-28	$0.57	$1,609,293,420	7 / 18
2026-07-29	$0.57	$1,609,293,420	7 / 18
2026-07-30	$0.57	$1,609,293,420	7 / 18
2026-07-31	$0.57	$1,609,293,420	7 / 18
2026-08-01	$0.51	$1,600,965,875	12 / 14
2026-08-02	$0.57	$1,609,293,420	7 / 18
2026-08-03	$0.57	$1,609,293,420	7 / 18
2026-08-04	$0.57	$1,609,293,420	7 / 18
2026-08-05	$0.58	$1,612,030,530	7 / 18
2026-08-06	$0.58	$1,603,704,764	12 / 14
2026-08-07	$0.58	$1,603,704,764	12 / 14
2026-08-08	$0.58	$1,612,030,530	7 / 18
2026-08-09	$0.58	$1,612,030,530	7 / 18
2026-08-10	$0.58	$1,612,030,530	7 / 18
2026-08-11	$0.58	$1,612,030,530	7 / 18
2026-08-12	$0.58	$1,612,030,530	7 / 18
2026-08-13	$0.58	$1,603,704,764	12 / 14
2026-08-14	$0.58	$1,603,704,764	12 / 14
2026-08-15	$0.58	$1,603,704,764	11 / 14
2026-08-16	$0.58	$1,603,704,764	11 / 14
2026-08-17	$0.58	$1,603,704,764	11 / 14
2026-08-18	$0.58	$1,603,704,764	12 / 14
2026-08-19	$0.58	$1,603,704,764	12 / 14
2026-08-20	$0.58	$1,603,704,764	12 / 14
2026-08-21	$0.05	$1,678,502,526	12 / 14
2026-08-22	$0.05	$1,678,502,526	12 / 14
2026-08-23	$0.05	$1,678,502,526	12 / 14
2026-08-24	$0.05	$1,678,502,526	12 / 14
2026-08-25	$0.05	$1,678,502,526	12 / 14
2026-08-26	$0.05	$1,678,502,526	12 / 14
2026-08-27	$0.05	$1,678,502,526	12 / 14
2026-08-28	$0.05	$1,678,502,526	12 / 14
2026-08-29	$0.05	$1,678,502,526	12 / 14
2026-08-30	$0.12	$1,678,502,499	12 / 14
2026-08-31	$0.12	$1,678,513,082	12 / 14
2026-09-01	$0.12	$1,678,513,082	12 / 14
2026-09-02	$0.13	$1,680,146,415	12 / 14
2026-09-03	$0.09	$1,681,808,638	12 / 14
2026-09-04	$0.09	$1,681,806,249	12 / 14
2026-09-05	$0.09	$1,681,806,249	12 / 14
2026-09-06	$0.09	$1,681,806,249	12 / 14
2026-09-07	$0.09	$1,681,806,249	12 / 14
2026-09-08	$0.09	$1,681,806,249	12 / 14
2026-09-09	$0.09	$1,681,806,249	12 / 14
2026-09-10	$0.09	$1,681,806,249	12 / 14
2026-09-11	$0.09	$1,681,806,249	12 / 14
2026-09-12	$0.09	$1,681,806,249	12 / 14
2026-09-13	$0.08	$1,680,795,665	12 / 14
2026-09-14	$0.08	$1,680,795,665	12 / 14
2026-09-15	$0.08	$1,680,795,665	12 / 14
2026-09-16	$0.08	$1,680,795,665	12 / 14
2026-09-17	$0.08	$1,680,795,665	12 / 14
2026-09-18	$0.08	$1,680,795,665	12 / 14
2026-09-19	$0.08	$1,680,795,665	12 / 14
2026-09-20	$0.08	$1,680,795,665	12 / 14
2026-09-21	$0.08	$1,680,795,665	12 / 14
2026-09-22	$0.08	$1,680,795,665	12 / 14
2026-09-23	$0.08	$1,680,795,665	12 / 14
2026-09-24	$0.08	$1,680,795,665	12 / 14
2026-09-25	$0.08	$1,680,795,665	12 / 14
2026-09-26	$0.08	$1,680,795,665	12 / 14
2026-09-27	$0.08	$1,680,795,665	12 / 14
2026-09-28	$0.08	$1,680,795,665	12 / 14
2026-09-29	$0.08	$1,680,795,665	12 / 14
2026-09-30	$0.06	$1,680,795,665	12 / 14
2026-10-01	$0.06	$1,680,795,665	12 / 14
2026-10-02	$0.06	$1,680,795,665	12 / 14
2026-10-03	$0.06	$1,680,795,665	12 / 14
2026-10-04	$0.06	$1,680,795,665	12 / 14
2026-10-05	$0.06	$1,680,773,443	12 / 14
2026-10-06	$0.06	$1,680,773,443	12 / 14
2026-10-07	$0.07	$1,680,773,443	12 / 14
2026-10-08	$0.07	$1,680,900,432	12 / 14
2026-10-09	$0.07	$1,680,900,432	12 / 14
2026-10-10	$0.07	$1,680,900,432	12 / 14
2026-10-11	$0.07	$1,680,928,210	12 / 14
2026-10-12	$0.07	$1,680,928,210	12 / 14
2026-10-13	$0.03	$1,680,383,765	12 / 14
2026-10-14	$-0.07	$1,678,022,971	12 / 14
2026-10-15	$-0.13	$1,677,589,638	12 / 14
2026-10-16	$-0.14	$1,680,156,658	12 / 15
2026-10-17	$-0.14	$1,680,156,658	12 / 15
2026-10-18	$-0.14	$1,680,156,658	12 / 15
2026-10-19	$-0.14	$1,680,156,658	12 / 15
2026-10-20	$-0.12	$1,680,046,131	12 / 15
2026-10-21	$-0.26	$1,655,097,642	12 / 15
2026-10-22	$-0.26	$1,655,097,642	12 / 15
2026-10-23	$-0.42	$1,652,582,247	12 / 15
2026-10-24	$-0.42	$1,652,582,247	12 / 15

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	23	2
2026-06-01	22	2
2026-07-01	22	2
2026-08-01	20	3
2026-09-01	19	3
2026-10-01	21	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 21 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Morgan StanleyOct 21 · prior Aug 11

$97.00 → $87.00-10.3%

Piper SandlerOct 19 · prior Aug 11

$115.00 → $120.00+4.3%

UBSOct 15

$92.00New observation · no comparable prior

BarclaysOct 7

$156.00New observation · no comparable prior

$0$85.80$171.60

1 raises · 1 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Execute capital allocation including $500M stock buybackDirect metric needs a verified mapping
Manage operating losses and improve operating incomePublished status: Under Pressure
Grow revenue through Attruby and new product launchesProduct revenue: $222.44M

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.2%Typical daily move · historical

Downside history

-29.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Bridgebio Pharma, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-focused biotech company, not a profitable compounder today. The long-term thesis is intact, with recent performance holding in the top half of its industry, though management execution is rated volatile and the evidence has medium confidence.

What's priced into Bridgebio Pharma, Inc.

BBIO trades at a premium to peers, while the valuation evidence describes that premium as durable and justified. The expectations gap is negative, which suggests expectations may be demanding; confidence in that reading is low, and no valuation fragility gates have fired.

What the fundamentals likely do

Near term, revenue growth is supported by Attruby: total revenue rose from $194.5 million in the first quarter of 2026 to $243.7 million in the second, mainly from U.S. Attruby sales. The company remains loss-making, and the risk of another earnings miss is elevated after consecutive misses. Over the multi-year view, three submitted NDAs and management’s stated launch plans provide a possible next source of growth, but regulatory progress is mixed.

What Bridgebio Pharma, Inc. hinges on

The thesis depends on continued Attruby growth, successful progress through regulatory review, and execution on planned launches. A guidance cut at the next call would be a meaningful negative, while continued strength from major healthcare companies could support the sector backdrop. Weakening jobs data may also increase recession concerns and weigh on healthcare names.